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The high failure rate of antidepressant clinical trials is due in part to a high magnitude of placebo
response and considerable variance in placebo response. In some recent trials enhanced patient inter-
view techniques consisting of Structured Interview Guide for the MontgomeryeAsberg Depression
Rating Scale (SIGMA) interviews, audiotaping of patient interviews and ‘central’ appraisal with Rater
Applied Performance Scale (RAPS) criteria have been implemented in the hope of increasing reliability
and thus reducing the placebo response. However, the data supporting this rationale for a change in
patient interview technique are sparse.
We analyzed data from depressed patients assigned to placebo in antidepressant clinical trials con-
ducted at a single research site between 2008 and 2012. Three trials included 34 depressed patients
undergoing SIGMA depression interviews with taping and RAPS appraisal and 4 trials included 128
depressed patients using traditional interview methods.
Using patient level data we assessed the mean decrease in total MADRS scores and the variability of
the decrease in MADRS scores in trials using SIGMA interviews versus trials using traditional interviews.
Mean decrease in total MADRS score was signiﬁcantly higher in the 3 trials that used SIGMA in-
terviews compared to the 4 trials using traditional interviews (M ¼ 13.0 versus 8.3, t(df ¼ 160) ¼ 2.04,
p ¼ 0.047). Furthermore, trials using SIGMA had a larger magnitude of response variance based on
Levene’s test for equality of variance (SD ¼ 12.3 versus 9.4, F ¼ 7.3, p ¼ 0.008).
The results of our study suggest that enhanced patient interview techniques such as SIGMA interviews,
audiotaping and RAPS appraisal may not result in the intended effect of reducing the magnitude of
placebo response and placebo variance.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The longstanding notion that antidepressant-placebo differ-
ences in antidepressant clinical trials were large, predictable and
stable was refuted more than a decade ago (Walsh et al., 2002;
Khan et al., 2002a). Walsh et al. showed that the magnitude ofh Center, 1951 e 152nd Place
cett@nwcrc.net (J. Faucett).
r Ltd. Open access under CC BY-NC-NDplacebo response had been increasing for a few decades and Khan
et al. showed that more than 50% of antidepressant clinical trials
with approved antidepressants failed to show statistical signiﬁ-
cance over placebo, mostly due to the high magnitude of placebo
response.
Some researchers (Leon et al., 1995; Perkins et al., 2000; Lipsitz
et al., 2004) suggested that much of this failure can be attributed to
low inter-rater and intra-rater reliability. Their argument was based
on the fact that the magnitude of symptom reductionwas large and
variable from one antidepressant trial to the next, anywhere from
10% to 50%.
Furthermore, the variance in the group of depressed patients
assigned to placebo is typically large as measured by the standard
deviation (SD). The SD in the depressed patients assigned to license.
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and at the end of the trial it is likely to be around nine or ten.
The view that increasing the reliability of ratings may reduce
the placebo response in antidepressant trials was supported
by data from Kobak et al. (2005, 2007) and Engelhardt et al. (2006)
who showed that the inter-rater reliability was low among
raters participating in antidepressant clinical trials. In addition,
Cogger (2007) conducted a post-hoc analysis of two antidepressant
trials and showed that raters who adhered to a structured format
and asked speciﬁc and focused questions showed larger
antidepressant-placebo differences than raters who did incomplete
or cursory evaluations. These data lent credence to the idea that
‘raters should be rated’ to improve trial outcome (Engelhart et al.).
Based on the ﬁndings above, a few independent companies
were set up to develop methods to improve the reliability of data in
antidepressant clinical trials. Speciﬁcally, a structured interview
format (SIGMA interview) for the MontgomeryeAsberg Depression
Rating Scale (MADRS; Montgomery and Asberg, 1979) was created
and proposed as the standard interview for antidepressant clinical
trials (Williams and Kobak, 2008). Second, raters located away from
the trial sites (‘central raters’) would conduct the depression in-
terviews via video-conferencing or via audiotaped interviews on
the phone using the SIGMA format.
Another alternative was to require raters at the trial sites (‘local
raters’) to use the SIGMA format during the trials and to audiotape
the interviews. The local raters would be scrutinized for their
‘adherence’ to SIGMA conventions throughout the trial by central
raters who were independent of the site. Then independent re-
viewers from the vendors review the taped interviews of the local
raters for interview format using the criteria outlined in the Rater
Applied Performance Scale (RAPS): Adherence, Follow-up, Clariﬁ-
cation, Neutrality, Rapport, and Accuracy of Ratings as outlined by
Lipsitz et al. (2004). We have termed this review an outside
appraisal.
Adherence was deﬁned as asking speciﬁc closed-ended ques-
tions followed by speciﬁc probes to deﬁne an ‘anchor point’ in the
MADRS scale. Clariﬁcation and follow-up relate to obtaining spe-
ciﬁc data from the depressed patient as to events that occurred over
the previous week. For example, the depressed patient is prompted
to recall the time to bed on each of the previous seven days, speciﬁc
number of awakenings and total sleep for each night.
Neutrality was deﬁned as maintaining a neutral research
rapport but not an empathic one as it was considered that such
empathy would enhance placebo response. The introduction of
these criteria into antidepressant clinical trials were based on
earlier reports (Lipsitz et al., 2004; Kobak et al., 2005) showing
increased reliability of RAPS compliant interviews.
Kobak et al. (2010) reported that the ‘central raters’ got a lower
placebo response than ‘local raters’. The authors attributed this
lower placebo response in part to lower pre-randomization mean
total MADRS scores by the ‘central raters’.
However, two reports have challenged the concept that SIGMA
interviews including audiotaping and RAPS appraisal lead to better
outcome. Oren et al. (2008) reported results from a trial of an
investigational medication versus escitalopram and placebo using
centralized raters that determined patient eligibility and assessed
the primary outcome measure. The central raters conducted eval-
uations with video-conferencing and were blinded to study design
and the week of the patient visit. The authors reported no signiﬁ-
cant difference between placebo and escitalopram and also the
reported results for the investigational medication were signiﬁ-
cantly worse than placebo (p ¼ 0.04).
More recently, Targum et al. (2013) reported results from a study
evaluating trial outcome differences based on themethod of rating:
‘central raters’ using a structured format and taping versus local siteraters. Outcome was evaluated using the Inventory of Depressive
Symptomatology-30 Item Clinician Version: IDSc30 (Rush, 2000)
and Quick Inventory of Depressive Symptomatology: QIDS (Rush
et al., 2003). A signiﬁcant difference between combination bus-
pirone treatment versus placebowas reported on the IDSc30 for the
site based ratings (p ¼ 0.030) whereas the centralized ratings did
not detect this difference (p ¼ 0.124) (details reported in Table 3 of
the Targum et al. publication).
Given this background we undertook the current study. Spe-
ciﬁcally, we evaluated the magnitude of placebo response and
response variance among depressed patients assigned to placebo in
seven recently conducted multi-center Phase II and Phase III anti-
depressant clinical trials, three of which used SIGMA interviews
with audiotaping and central ratings with four using traditional
interview methods similar to those used over a decade ago.
We hypothesized that the magnitude of placebo response and
the variance of placebo response would be lower in antidepressant
trials that used the SIGMA interview techniques with audiotaping
and central RAPS rating appraisal compared to the traditional non-
SIGMA MADRS interview techniques.
2. Methods
2.1. Background
Based on the publications by Cogger (2007) and Kobak et al.
(2007, 2010) a few independent companies (vendors) have set up
methods for evaluating depressed patients such as SIGMA in-
terviews with audiotaping of the rating interviews and outside
appraisal using the RAPS criteria. Some pharmaceutical companies
have chosen to implement such rater interview techniques but
others have not and instead continue to use traditional psychiatric
interview methods. Thus, the Northwest Clinical Research Center
(NWCRC) has been using the twomethods of rater interviews based
on the choice of the sponsoring pharmaceutical companies in a
random order without having any say in which method is selected.
As several of the agents in our study either remain in develop-
ment phase or have recently been submitted to the FDA for regu-
latory review, the data from the group assigned to antidepressants
remain conﬁdential and proprietary. Thus, the focus of our evalu-
ation was on response to patients assigned to placebo based on the
interview method used to conduct the trial.
2.2. Study selection
Between 2008 and 2012, the NWCRC was an investigative site
for twelve antidepressant clinical trials that used an acute, ran-
domized, double-blind, parallel-group and placebo controlled
design evaluating mono-therapy for Major Depressive Disorder
(MDD) Each of these trials excluded patients diagnosed with
Treatment Resistant Depression as speciﬁed by a failure to respond
to two or more antidepressants in the past.
Of the twelve trials, three used the newer interview rating
format that consisted of using SIGMA, and audio-taping of indi-
vidual patient evaluations at each visit (usually weekly) for six to
eight weeks. We were able to access the randomizations codes for
all of these three antidepressant trials.
One of the three trials that used SIGMA rating methods required
that an anonymous ‘central rater’ conduct a telephone interview
and taped the interview (Trial #1 in Table 1). In this trial the scores
reported by the central rater were considered the primary outcome
variable. The other two trials required the ‘local raters’ to follow the
SIGMA interview schedule and audiotape the interviews (Trial #2
and Trial #3 in Table 1). Speciﬁc written feedback was provided
throughout the trial to the raters as well as the Principal
Table 1
Years of conduct, antidepressant clinical trial characteristics and key mean total MADRS rating scale scores for the placebo arm of seven antidepressant clinical trials cate-
gorized by the method of depressed patient interviews.
Trial start date Trial duration Risk of placebo exposure N patients Mean age %Female Mean total
baseline MADRS
scores (SD)
Mean decrease in
total MADRS (SD)
%Symptom
reduction (SD)
Section 1: Trials using structured, video or audio-taped and appraised depression interviews managed by non-NWCRC vendors
Trial 1 2011 8 50% 12 37 8 31.0 (7.0) 15.2 (12.4) 48.4 (35.3)
Trial 2 2009 8 25% 10 40 60 37.7 (5.5) 12.3 (14.2) 34.6 (41.9)
Trial 3 2009 8 50% 12 38 58 35.8 (3.8) 11.3 (11.1) 31.5 (31.7)
Section 2: Trials using traditional depression clinical interview methods practiced at NWCRC
Trial 4 2008 8 50% 73 42 44 31.0 (3.7) 9.7 (9.5) 31.8 (31.4)
Trial 5 2009 5 33% 18 39 50 31.3 (3.8) 9.6 (7.4) 31.1 (24.5)
Trial 6 2010 6 33% 10 49 30 32.3 (4.4) 5.5 (9.8) 17.7 (30.1)
Trial 7 2012 8 50% 27 41 52 31.2 (4.4) 4.9 (9.5) 15.3 (34.3)
Abbreviations: MADRS ¼ MontgomeryeAsberg Depression Rating Scale, SD ¼ Standard Deviation.
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the rater’ publication by Engelhardt et al. (2006).
Of the nine trials that used the traditional non-SIGMA MADRS
interview method for evaluating patients, we were able to obtain
randomization codes for only four of them [it is common to obtain
around 50% of randomization codes as previously reported in Khan
et al. (2002b)].
2.3. Inclusion/exclusion of the patients
Aside from the method of patient evaluation, the two groups of
trials were similar in design and patient population. All of the trials
recruited male and female adult patients between the ages of 18
and 70 with a diagnosis of MDD based on Diagnostic and Statistical
Manual of Mental Disorders e Fourth Edition criteria (American
Psychiatric Association, 2000). The patients all agreed to an
informed consent detailing study procedures and were speciﬁcally
informed of the possibility of being recorded during the depression
interview. All included female patients were not pregnant and
agreed to use adequate contraception during the studies.
Depressed patients with signiﬁcant physical or psychiatric
comorbidities were excluded from the studies as were patients
with established diagnosis of Treatment Resistant Depression. Pa-
tients with a history of substance abuse in the past six months were
excluded as were patients that required medications that were
excluded by the study protocol. Patients that did not have at least
one post-baseline follow-up measurement were excluded from the
study.
There were no systematic differences in patients recruited for
trials that used SIGMA interview methods with taping and outside
appraisal as compared to the patients recruited for trials that used
traditional interviews. The exclusion/inclusion criteria were ho-
mogeneous across the trials. Patients were randomly enrolled into a
trial using either methods of interview based on factors including
clinical evaluation date and enrollment start and stop dates for the
respective trials.
2.4. Synthesis and analysis of data
After receiving randomization codes from pharmaceutical
company sponsors we tabulated the clinical trial characteristics of
the studies. We recorded the trial start date and duration of the
double-blind treatment phase of each of the trials. We then tabu-
lated the patient level data by creating a database using the sta-
tistical software SPSS (version 19.0).
The database consisted of a patient identiﬁer, baseline MADRS
score, last observation carried forward MADRS score as well as
information on the age and sex of each patient enrolled. Only thepatients that were assigned to placebo were included in the data-
set. In other words, all of our comparisons were done using indi-
vidual patient level data as each patient was rated by either the
traditional method or the structured method depending on which
trial they were enrolled.
In order to review and report the mean patient level outcomes
for each individual trial, a numerical code was created to represent
each of the seven individual trials. A numerical code was then
created to quantify the rating style used in the trials as the inde-
pendent variable. All of the patients that were enrolled in trials
that were conducted using traditional patient rating methods
were coded 1, with all of the patients enrolled in trials that were
conducted using the structured method of rating the patients
coded 2.
We conducted three statistical tests during our analysis of the
two groups of trials. First, we used and independent samples t test
to compare the baseline scores. To statistically evaluate the
outcome for all of these patients assigned to placebo we conducted
an independent samples t test comparing the mean decrease in
MADRS change scores based on the type of patient interview
method used (patients that were interviewed using the traditional
rating method versus those interviewed using the SIGMA method
with taping and RAPS appraisal). Levene’s test for equality of vari-
ance was used to evaluate the similarity of change score distribu-
tion between the two sets of trials.
3. Results
A total of 162 patients were assigned to placebo in the seven
clinical trials that were included in our study. The mean age of the
patients was 41 years and 56% of the patients were male. There
were no signiﬁcant age differences or differences in gender distri-
bution between the trials using SIGMA interviews versus trials
using traditional non-SIGMA MADRS interviews.
As shown in Table 1 the trials were dichotomized into two
groups for our evaluation: trial #1 used central raters who followed
the SIGMA interview format that was taped and appraised using
RAPS method. Trials #2 and #3 used local raters who followed the
SIGMA format, with interviews being taped and appraised by
outside reviewers. Trials #4 to #7 used the traditional psychiatric
interview format to obtain MADRS scores.
The results of our statistical comparison based on the rating
style used in the trials are shown as Table 2. Our ﬁrst comparison of
the baseline scores indicated that the patients enrolled in trials that
used SIGMA interviews had signiﬁcantly higher scores at the pre-
randomization visit compared to the patients enrolled in trials
using traditional interviews (M ¼ 34.7  6.1 versusM ¼ 31.2  3.9,
t(df ¼ 160) ¼ 4.08, p < 0.001.
Table 2
Comparison of outcome with placebo treatment as measured by the mean decrease in total MADRS scores and the variance in the mean decrease in the total MADRS score as
measured by the standard deviation among the patients enrolled in seven antidepressant trials.a
Trials (N ¼ 3) using structured,
video or audio-taped and appraised
depression interviews
managed by non-NWCRC vendors
Trials (N ¼ 4) using traditional
depression clinical interview
methods practiced at NWCRC
Probability valueb,c
N patients assigned to placebo 34 158 —
Mean (Standard Deviation) baseline score 34.7 (6.1) 31.2 (3.9) t(df ¼ 160) ¼ 4.1, p < 0.001
Mean decrease in total MADRS score 13.0 8.4 t(df ¼ 160) ¼ 2.04, p ¼ 0.047
Variance of the mean decrease in total
MADRS Score reported as standard deviation
12.3 9.4 F ¼ 7.3, p ¼ 0.008
Abbreviation: MADRS ¼ MontgomeryeAsberg Depression Rating Scale.
a ThemeanMADRS score decrease and variance of themean decrease were calculated using patient-level data from trials using traditional rating methods (N¼ 128) as well
as the trials using structured rating methods (N ¼ 34), they were not calculated using cumulative trial level data.
b An independent samples t test was used to evaluate the signiﬁcance of difference in MADRS change scores.
c The variance of the groups was signiﬁcantly different based on Levene’s test for equality of variance. The reported probability value does not assume equal variances.
A. Khan et al. / Journal of Psychiatric Research 51 (2014) 88e92 91Our evaluation of outcome of the patients assigned to placebo
indicated that the mean decrease in MADRS score was signiﬁcantly
larger in the patients that were interviewed using SIGMA with
audiotaping and outside RAPS appraisal of the interviews
(M ¼ 13.0) versus the patients that were interviewed using the
traditional interview methods (M ¼ 8.3), t(df ¼ 160) ¼ 2.04,
p ¼ 0.047.
Lastly, we compared the variance of the mean MADRS decrease
scores of two groups of patients and found that the patients
interviewed using SIGMA with audiotaping and outside RAPS
appraisal had signiﬁcantly greater variability (SD¼ 12.3) versus the
trials using traditional patient interview methods (SD ¼ 9.4),
F ¼ 7.3, p ¼ 0.008.
4. Discussion
The aim of the study was to evaluate if structured SIGMA in-
terviews that are audiotaped and appraised by central raters using
RAPS criteria reduced the magnitude of placebo response in anti-
depressant clinical trials. Contrary to expectations we found that
the magnitude of placebo response as well as the variance in pla-
cebo response was signiﬁcantly higher in the antidepressant clin-
ical trials that used the newer techniques as compared to the
traditional techniques.
The results of our study follow the results reported by Oren et al.
(2008) who found a placebo decrease of 34% in a trial conducted
using these techniques that was nearly identical to the response to
the active comparator escitalopram. This sample consisted of a
multi-site study including 160 depressed patients (escitalopram
N ¼ 52, placebo N ¼ 108). As has been shown, more than a 30%
mean decrease from total pre-randomization scores in the placebo
group is a harbinger of antidepressant clinical trial failure (Khan
et al., 2003).
Our ﬁndings also parallel those of Targum et al. (2013) who
compared the data from ratings by ‘local raters’ for IDSc30 and
showed an almost ﬁve fold greater difference in combination drug
therapy for depression versus placebo when compared to ‘central
raters’ evaluations (4.84 versus 1.07, Table 3, p. 949). The Targum
et al. study consisted of a sample of 101 depressed patients (com-
bination therapy N ¼ 67, placebo ¼ 34).
On the other hand our ﬁndings are very different from those
reported by Kobak et al. (2010). We found a signiﬁcantly higher
baseline score in the trials that used SIGMA interviews with taping
and outside appraisal by RAPS criteria whereas Kobak et al. re-
ported that site interviewers inﬂated the baseline score as
compared to central raters of the same patients. In addition, Kobak
et al. found that the decrease in placebo group was larger for site
raters than it was for central raters. Our study on the other handfound a signiﬁcantly larger and more variable placebo response in
pivotal clinical trials using SIGMA interview methods as compared
to the trials using traditional interview methods.
Thus, three of four studies that have prospectively evaluated
enhanced rating techniques including SIGMA interviews, audio-
taping and outside appraisal do not support the contention that
these techniques decrease the placebo response or response vari-
ance or increase antidepressant-placebo differences. Even if these
new techniques resulted in data similar to that derived from
traditional interviews, the unnecessary burden in both cost and
time to use SIGMA ratings with central RAPS appraisal is difﬁcult to
justify.
The implication of increasing variance is that the power calcu-
lations for such trials need review. Speciﬁcally, an increase in
variance of 30%would decrease the power by a third ormore. So far,
to our knowledge no antidepressants have been approved by the
FDA as a result of trials that use the SIGMA rating techniques with
taping and outside appraisal of the patient interviews.
In trying to understand our unexpected ﬁnding we asked
several raters about their rating experiences. In discussing her re-
action to the structured and appraised interview one rater said,
“You are aware that your adherences to the exact language of the
form as well as your assessment skills are being monitored. Of
course, the interviewer begins to focus more on the details of the
interview form and her own performance and attention is less
available to focus on the patient. What is lost is the level of infor-
mation that comes from a more global perception of the patient
presentation, including non-verbal cues”.
Another rater had this to say about the SIGMA ratings with
audiotaping and RAPS appraisal. “These are question and answer
sessions and do not get into an in-depth exploration of the patient’s
world that is unique to the individual. Also, I feel that patients feel
that they are being scrutinized for good behavior and have to
present themselves in the best light and are reluctant to criticize
their experience. Simply put the patients become actors and seem
to perform for the ratings”.
The results of our study along with those of Oren et al. (2008),
Kobak et al. (2010) and Targum et al. (2013) represent only the
tip of the iceberg in regards to evaluating the newer depression
interview methods. Many more antidepressant clinical trials have
been conducted over the past ﬁve years using the taped SIGMA
interviews with outside appraisal, or with other newly introduced
interview techniques. It is important that the data from trials
conducted using these interviews be scrutinized by their sponsors
and by the vendors who practice these interview techniques.
Until then, the question of whether structured and taped
interview techniques may help in obtaining a lower magnitude of
placebo response, lower placebo variance and potentially increased
A. Khan et al. / Journal of Psychiatric Research 51 (2014) 88e9292antidepressant-placebo differences requires further research.
Simply put, the concept of increased reliability in patient interviews
may not simply translate into a decrease in the magnitude of pla-
cebo response and its variance. It is possible that these phenomena
may be more related to the clinical skills of the individual rater
rather than reliability of ratings.
In summary, the results of our study suggest that enhanced
patient interview techniques such as SIGMA interviews, audiotap-
ing and RAPS appraisal may not result in the intended effect of
reducing the magnitude of placebo response and placebo variance,
but may rather have the unintended consequence of increasing or
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